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Abstract:
In many disease areas, commonly used long-term clinical endpoints are 
becoming increasingly difficult to implement due to long follow-up times 
and/or increased costs. Shorter-term surrogate endpoints are urgently 
needed to expedite drug development, the evaluation of which requires 
robust and reliable statistical methodology to drive meaningful clinical 
conclusions about the strength of relationship with the true long-term 
endpoint. This paper uses a simulation study to explore one such 
previously proposed method, based on information theory, for evaluation 
of time to event surrogate and long-term endpoints, including the first 
examination within a meta-analytic setting of multiple clinical trials with 
such endpoints. 
The performance of the information theory method is examined for 
various scenarios including different dependence structures, surrogate 
endpoints, censoring mechanisms, treatment effects, trial and sample 
sizes, and for surrogate and true endpoints with a natural time-ordering. 
Results allow us to conclude that, contrary to some findings in the 
literature, the approach provides estimates of surrogacy that may be 
substantially lower than the true relationship between surrogate and true 
endpoints, and rarely reach a level that would enable confidence in the 
strength of a given surrogate endpoint. As a result, care is needed in the 
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Abstract
In many disease areas, commonly used long-term clinical endpoints are becoming increasingly 
difficult to implement due to long follow-up times and/or increased costs. Shorter-term surrogate 
endpoints are urgently needed to expedite drug development, the evaluation of which requires 
robust and reliable statistical methodology to drive meaningful clinical conclusions about the 
strength of relationship with the true long-term endpoint. This paper uses a simulation study to 
explore one such previously proposed method, based on information theory, for evaluation of 
time to event surrogate and long-term endpoints, including the first examination within a meta-
analytic setting of multiple clinical trials with such endpoints.
The performance of the information theory method is examined for various scenarios including 
different dependence structures, surrogate endpoints, censoring mechanisms, treatment effects, 
trial and sample sizes, and for surrogate and true endpoints with a natural time-ordering. Results 
allow us to conclude that, contrary to some findings in the literature, the approach provides 
estimates of surrogacy that may be substantially lower than the true relationship between 
surrogate and true endpoints, and rarely reach a level that would enable confidence in the 
strength of a given surrogate endpoint. As a result, care is needed in the assessment of time to 
event surrogate and true endpoints based only on this methodology.
1. Introduction
A major component in the design of any clinical trial is the selection of a primary endpoint that 
reliably reflects clinical benefit for patients. Such endpoints are needed to estimate the necessary 
sample size and duration of a clinical trial, and are selected such that a positive result will lead to 
a beneficial impact to patients and healthcare systems. While many therapeutic areas have 
established gold standards for endpoint selection, these are being challenged by the increasing 
































































follow-up times required to reach endpoint maturity, increased costs and the need to provide 
effective treatments to patients in as short a time as possible. Such pressures have led to a sharp 
increase in research relating to endpoint choice, and notably in the area of surrogate endpoints. 
These short-term endpoints are designed to be used as replacements for gold standard clinical 
endpoints that are currently accepted by regulators, and as such require thorough investigation to 
ensure that they are meaningful and can predict long-term benefit for patients.
A number of statistical methodologies to assess the relationship between a potential surrogate 
endpoint and long-term (or ‘true’) endpoint have been proposed in the literature, including the 
first initial framework of Prentice (1989)[1], subsequent measures based on single trials[2] and 
meta-analytic measures.[3]-[10] A desirable feature of any methodology in this setting is that there 
is consistency in interpretation of the results across different proposed surrogate endpoint types, 
to allow comparison of different surrogate candidates. Furthermore, it is highly desirable that 
results and corresponding conclusions are consistent between different methodologies, to avoid a 
situation where different conclusions are drawn purely due to the choice of statistical 
methodology applied. Finally, it is imperative that results of any surrogacy evaluation accurately 
reflect the true underlying predictive ability of the surrogate endpoint under investigation.  
However, many of the methods currently available to assess potential surrogates have different 
assumptions and modelling structures dep nding on the endpoints under investigation[11], and 
comparability of surrogacy measures across these different techniques has not been established. 
The need for unified approaches that can incorporate many different endpoint types is therefore 
apparent, as is the need for comparative assessments across multiple proposed methodologies.
The most commonly used methodology for surrogacy assessment is the two-stage meta-analytic 
approach proposed initially by Buyse et al. (2000),[4], and extended by Burzykowski et al. 
(2001)[6] for time-to-event endpoints. This method has been used in a number of real-life 
applications, for example in leukaemia[12], follicular lymphoma[13] and other non-Hodgkins 
lymphomas[14]. However, as noted by Alonso and Molenberghs (2007)[10], the methodology has 
limitations in that it needs to be specifically adapted for different endpoint types and does not 
provide the unified interpretation that is highly desired. The approach also requires joint 
modelling of endpoints that can be complex. Further, Dimier and Todd (2017)[15] illustrated that 
the time to event version of the method, which is based on joint modelling of surrogate and true 
endpoints using copula models[6], can be adversely affected when used to assess endpoints that 
are not ‘symmetrical’, i.e. time to event endpoints that have a natural time ordering such that one 
cannot be longer than the other. 
In a systematic review of surrogate endpoint methodology, Ensor et al. (2016)[16] recognise the 
need for unified approaches and noted that the information theory method proposed by Alonso 
and Molenberghs (2007)[10] has this advantage over the two-stage meta-analytic approach.  The 
information theory method does not require definition of complicated joint distributions for 
































































surrogate and true endpoints in order to assess the relationship between them, and measures of 
surrogacy can be calculated using parameters that are routinely available in standard software 
packages and that are familiar to many statisticians. Importantly, the information theory 
approach does not make any assumptions of endpoint symmetry, and it has been speculated that 
it can be considered appropriate for the evaluation of time-ordered endpoints such as exploration 
of progression-free survival (time to disease progression or death) as a surrogate for overall 
survival (time to death) by considering the time difference between the surrogate and true 
endpoints as the true outcome of interest (Pryseley et al., 2011)[17]. This is considered of high 
importance in settings where long-term survival is becoming the primary challenge for timely 
conduct of new clinical trials. 
The purpose of this paper is to investigate the information theory approach in the setting where 
results from several trials are available for assessing surrogacy (i.e. a meta-analytic context).  
This reflects the scenario most encountered in practice, and the most relevant for evaluating 
surrogacy over a variety of important clinical factors, such as mechanisms of action of different 
therapies and across different patient populations.  The aim is to assess the performance of the 
method in estimating trial and individual level surrogacy in the setting of two time-to-event 
endpoints and for a variety of underlying strengths of surrogacy, sample sizes and surrogate 
endpoint candidates. While the endpoints are chosen to be reflective of oncology clinical trials, 
findings are applicable to all types of time-to-event endpoint. A number of new questions are 
being addressed by this research, namely how well the method performs when being applied in 
the important meta-analytic setting, including estimation of trial-level surrogacy in this setting, 
exploration of how it might be impacted by different dependency relationships between surrogate 
and true endpoints, and whether inclusion of information directly relating to the true long-term 
endpoint impacts the estimated strength of surrogacy. In Section 2 brief details of the 
information theory method designed for use with time-to-event endpoints are provided, followed 
in Section 3 by a description of a simulation study conducted to investigate the methodology.  
Finally results and discussion of identified challenges are given in Sections 4 and 5 respectively. 
Data sharing is not applicable to this article as no new data were created or analyzed in this 
study.
2. Information Theory Approach to Evaluating Surrogates
The value of a potential surrogate endpoint is commonly assessed using two measures; 
individual-level surrogacy and trial-level surrogacy [11]. Individual-level surrogacy measures the 
ability of a surrogate outcome to predict a long-term outcome for an individual patient, whereas 
trial-level surrogacy measures how well the unobserved treatment effect on the long-term 
endpoint can be predicted using the observed treatment effect on the surrogate endpoint. Both 
measures of surrogacy are considered important; while the individual-level provides information 
































































on the prognostic value of the surrogate outcome for an individual patient, the trial-level measure 
provides a critical evaluation of whether a strong treatment effect on the surrogate endpoint will 
lead to meaningful long-term clinical benefit at a population level. Both measures of surrogacy 
are of use to regulatory authorities responsible for making decisions based on the expectation of 
long-term benefit for patients. 
Alonso and Molenberghs (2007)[10] first proposed the information theory measure as a way to 
evaluate both individual and trial level surrogacy, with key benefits including the applicability to 
many different endpoint types, and a unified interpretation of surrogacy measures across multiple 
surrogate endpoints. While the surrogacy measures based on this approach are calculated for 
single trials, a meta-analytic form can be estimated by taking a weighted average of the trial-
level measures. The approach has been explored in the binary and continuous setting by Alonso 
and Molenberghs (2007)[10], and in the time-to-event setting by Pryseley et al. (2011) [17]. 
With the introduction of censored data that is expected in time to event endpoints, the work of 
O’Quigley & Flandre (2006)[18] suggests that the proposed information theory measure of 
individual-level surrogacy can be adversely impacted, and so Pryseley et al. (2011) [17] conducted 
further work to determine which of a selection of alternative measures could be used within the 
same framework to appropriately handle censored data. Results of this investigation suggest that 
one measure, proposed by Xu and O'Quigley (1999)[19] and based on a dependence measure for 
proportional hazards models, could be recommended for further use in evaluating individual-
level surrogacy within an information theory context, maintaining the property of unified 
interpretability. The originally-proposed information theory based measure of trial-level 
surrogacy is unaffected by censoring, allowing it to be used immediately with time-to-event 
endpoints. 
Suppose there exist data from a single clinical trial containing j=1,…,n patients, with surrogate 
and true outcomes denoted Sj and Tj respectively. To estimate individual-level surrogacy in this 
trial using the information theory approach, two Cox proportional hazards models are assumed, 
as follows:
1) ,𝐻0: λ𝑡(t│Z) = λ0𝑡(𝑡)exp (𝛽𝑡Z𝑗)
2) ,𝐻1: λ𝑠𝑡(t│Z(t)) = λ0𝑠𝑡(𝑡)exp ( 𝛽1Z𝑗 + 𝛽2S𝑗(𝑡))
where denotes the baseline hazard at time t,  denotes the baseline hazard at time t λ0𝑡(t) λ0𝑠𝑡(t)
for a model adjusting for the surrogate outcome,   and  denote constant covariate β𝑡, β1 β2
coefficients,  denotes the assigned treatment group and  denotes a vector of time-Z𝑗 𝑍(𝑡)
dependent covariates that includes treatment group. Only covariates of treatment and surrogate 
outcome will be discussed herein; the addition of other covariates does not impact on the 
procedure for calculation of the surrogacy measures. In model H1, the covariate representing the 
































































surrogate endpoint is reflected as a time-varying value, to denote whether the surrogate event has 
occurred or not at time t.
In this model representation, H0 corresponds to a model where  is assumed to be zero, such 𝛽2
that the surrogate has no effect on T and surrogacy is poor.  The ‘alternative’ model, H1, 
corresponds to a model where  has no restriction, thereby providing the ‘information gain’ that 𝛽2
comes from inclusion of the surrogate outcome, S, in the model. Quantification of the 
information difference between these two models therefore indicates the strength of prediction of 
outcome T that can be gained through knowledge of the surrogate outcome, S. Using the notation 
of Pryseley et al. (2011) [17], the recommended measure of individual-level surrogacy for the trial 
is defined as
,𝑅2𝑋𝑂𝑄 = 1 ― exp ( ― Γ(H1,H0;𝛽))
where  represents the true values of  and𝛽 (𝛽1, 𝛽2)
,Γ(H1,H0;𝛽) = 2∫𝑇∫𝑍log[𝑔(𝑧|𝑡;𝛽)𝑔(𝑧|𝑡;𝛽 )] 𝑔(𝑧│𝑡;𝛽) 𝑑𝑧𝑑𝐹(𝑡)
where the parameter denotes the value maximising the likelihood of model H0 with respect to 𝛽 
, g(z|t,β) denotes the conditional distribution of Z|T and F(t) denotes the marginal distribution 𝛽
function of T.  In practice, the Kaplan-Meier function is proposed (Kaplan and Meier, 1958)[20] 
as the marginal distribution F(t), and for the conditional distribution of Z|T at each event time, 
Xu and O'Quigley (1999) [19] propose to use the conditional probability of patient j having an 
event at time t given their covariate values at that time, based on the partial likelihood of the Cox 
proportional hazards models (Cox, 1972)[21]. Xu and O'Quigley (1999) [19] note that the 𝑅2𝑋𝑂𝑄 
measure is dependent on the total duration of follow-up of the trial, and propose an adjusted 
version that accounts for this, dividing by the total period of follow-up. 
This value of can be calculated using quantities estimated from standard software 𝑅2𝑋𝑂𝑄 
packages, making it very appealing, and confidence intervals can be constructed by re-
calculating the measure using the confidence limits for the surrogate covariate coefficient 𝑅2𝑋𝑂𝑄 
using the same approach. In the meta-analytic setting, can be calculated for each trial and a 𝑅2𝑋𝑂𝑄 
weighted estimate used to provide an overall measure.
For the time to event setting, Pryseley et al. (2011) [17] noted that the information theory approach 
can also be immediately applied to time-ordered endpoints, where S<=T, for example when 
using overall survival as the true endpoint where all potential surrogates are restricted to occur 
prior to T. Instead of modelling the impact of the surrogate outcome directly on the true outcome 
in the Cox proportional hazards models, the time between these two endpoints can be used as the 
outcome measure. For example, in the context being described herein, use of post-progression 
































































survival as a time-to-event endpoint can be used in place of T, with the status of the surrogate 
outcome (event or not) being used as the covariate in model H1. 
At the trial-level, multiple trials are needed to evaluate the relationship between treatment effects 
on S and T, and so a meta-analysis is required. In the information theory framework, the same 
concepts can be applied to trial-level surrogacy in estimating how much of the uncertainty in 
treatment effect on the true endpoint can be reduced through knowledge of the treatment effect 
on the surrogate endpoint. Alonso and Molenberghs (2007)[10] note that under the assumption of 
a linear relationship between treatment effects on S and T, the square of the correlation 
coefficient between treatment effects immediately has an interpretation from the information 
theory perspective. Therefore, the trial-level surrogacy, denoted R2trial, can be estimated by 
taking the square of the correlation coefficient between treatment effects on T from model H0 
and the treatment effect on S estimated from the following model:
1) .𝐻𝑠: λ𝑠(s│Z) = λ0𝑠(s)exp (β𝑆Z𝑗)
As before, denotes the baseline hazard at time s, and denotes a constant covariate λ0𝑠(s) β𝑠 
coefficient for treatment, .Z𝑗
The only published evaluation of the information theory approach in the context of time-to-event 
endpoints is that of Pryseley et al. (2011) [17], who conducted a simulation study to assess 
individual-level surrogacy for a time-to-progression endpoint (TTP: defined as time from study 
entry to the earliest sign of disease progression) as a surrogate for overall survival (OS: defined 
as time from study entry to death). This study considered individual trials containing 100-2000 
patients, with no censoring and with 20-70% censoring, and for various true underlying 
individual-level surrogacy levels. 
Since the aforementioned investigation was based on data generated from only a single clinical 
trial, no consideration of the meta-analytic setting, nor of trial-level surrogacy, has been 
conducted in the literature for time to event endpoints. While research has been published for 
other endpoint types, estimation of treatment effects on time to event endpoints can be dependent 
on the level of censoring present in the data, and so it is not immediate that results of 
investigations from other endpoint types can be extrapolated to the time-to-event setting.   The 
question of how well the information theory approach can perform in a meta-analysis of time to 
event data therefore remains unanswered and is the primary goal of the research presented 
herein. Secondly, it is also of interest to assess whether the information theory method is 
sensitive to the underlying dependence structure of the surrogate and true endpoints within the 
clinical trials, which has been shown to cause issues for other surrogacy evaluation 
approaches[15]. Finally, it is of interest to explore the suggestion that the information theory 
approach can be used to reliably assess surrogacy of time-ordered endpoints, such as surrogates 
































































for overall survival. If so, this would be considered of extremely high value in settings where 
long survival times are hampering efforts to conduct new clinical trials of experimental therapies. 
Each of these research questions will be explored through the use of a simulation study, details 
of which are presented in Section 3.
3. Simulation Study
A key consideration in the set-up of a simulation study to assess any surrogacy evaluation 
method is how the underlying surrogacy (trial and individual) can be adequately controlled. 
Ideally, the parameter being estimated by the surrogacy approach would be directly controlled. 
However, the parameters that are required in calculation of the information theory method of 
individual-level surrogacy make this very difficult, as they are estimated from conditional 
models using the likelihood ratio, meaning that each sample would have a slightly different 
underlying value. 
Previous investigations of the measure have been based on datasets simulated according to 𝑅2𝑋𝑂𝑄 
a Cox proportional hazards model (Xu and O'Quigley, 1999) [19], where a single covariate was 
included in the model and the respective covariate coefficient was used to control the overall 
strength of association with the outcome variable. Whilst this allows for specification of the 
strength of this relationship, there could be considerable subjectivity in the selection of 
coefficient values, and the impact of this on the resulting estimation of is not currently 𝑅2𝑋𝑂𝑄 
clear. Additionally, the strength of covariate coefficient, or hazard ratio, may be interpreted very 
differently depending on the disease context. 
Instead, the study of Pryseley et al. (2011) [17] was based on data generated using a Clayton 
copula function, controlling association between endpoints through the copula parameter, τ, 
which is designed to reflect the strength of association between S and T based on the chosen 
dependence structure. Whilst the value of τ may not perfectly reflect the true information 
theoretic measure of association, such an approach allows for overall control of individual (τ) 
and trial ( ) association levels, subject to sample variability, with a clear interpretation 𝑅2𝑡𝑟𝑖𝑎𝑙
(strength of association between S and T after adjusting for treatment and trial effects) and scale 
(ranging 0-1). In order to be consistent with the approach taken by Pryseley et al. (2011) [17], and 
to allow meaningful comparison across these simulation studies, data generation herein was also 
conducted using this copula model. To assess the robustness of the results to this approach, two 
different copula models were used to change the underlying dependence structure and evaluate 
whether this has any impact on the results. Further selected scenarios were also generated using 
an algorithm based on the lognormal distribution, that does not use a copula model; these 
scenarios are displayed in Table 1. A brief description of the simulation setup is provided below. 
































































In this study, a true endpoint of OS (defined as time from study entry to death) is of interest, to 
reflect the most challenging setting where surrogate endpoints are most needed. Surrogate 
endpoints of time to progression (TTP: defined as time from study entry to disease progression) 
and progression-free survival (PFS: defined as time from study entry to the earliest of disease 
progression or death) are considered, with the goal to evaluate how inclusion of data from the 
true endpoint into the surrogate definition might impact the performance of the methodology.
In all data generation methods, model parameters are chosen to reflect a scenario where the 
median value of the surrogate (5‐6 months) is approximately half of that of the true endpoint 
(11‐12 months). Treatment effects are chosen such that the effect on S (hazard ratio ~0.67) is 
slightly stronger than that on T (hazard ratio ~0.82), to reflect the potential influence of post-
progression therapies on the observed treatment effect on OS. Censoring is applied by drawing 
an exponential random variable and comparing to the simulated event values, scaling the random 
value to control the proporti n of censoring in the data. Since the true endpoint of interest is OS, 
the value of TTP as the surrogate is also censored by the true endpoint, if it occurs first. For PFS, 
when death occurs prior to progression, the patient is considered to have an event at the time of 
death, and additional censoring is not applied. In order to investigate the potential for false 
positive or false negative results, the strength of individual and trial-level surrogacy was varied 
from very low (0.2, to reflect a true lack of surrogacy) to very high (0.8, to reflect a very strong 
level of surrogacy).
Data Generation
Data generation using the Clayton copula was conducted using the conditional distribution 
method (Burzykowski et al. 2001)[6]. This algorithm draws two independent random variables 
from a Uniform(0, 1) distribution, which are then transformed to be distributed according to the 
joint survival function defined by the Clayton copula function, with strength of dependence 
controlled using the copula dependence parameter, τ. Once transformed, the two uniform random 
variables have the required shape and strength of association and can be further transformed to 
survival outcomes according to the desired marginal survivor functions. Based on these marginal 
functions, the joint survival function provides strong upper‐tail dependence and weaker 
lower‐tail dependence (see Burzykowski (2001)[6] for details). For consistency with previous 
studies, exponential marginal distributions were selected.
To generate data according to the dependence structure of the Gumbel copula, which provides 
stronger lower-tail dependence (i.e. at earlier event times) and weaker upper-tail dependence, the 
mixtures of powers algorithm described by Trivedi and Zimmer (2007)[22] was used, with 
parameters selected to ensure comparability of overall summary characteristics with the data 
generated using the Clayton copula.
































































In order to evaluate whether the use of copula functions may bias the data generation, 
lognormally-distributed data were also generated using an algorithm previously used in the 
context of comparing estimators of Kendall's τ (Hsieh, 2010)[23]. Using this method, the 
parameter that controls the association between endpoints remains as Kendall's τ, but the value is 
transformed for use within a covariance matrix of a bivariate normal distribution to control the 
strength of correlation between endpoints. Although this method also makes use of the joint 
distribution between the two endpoints, it is not reliant on the choice of copula. 
To generate individual values of surrogate and true outcomes using the lognormal data 
generation method, a three-step process was created. First, two variables, one for each of the 
surrogate and true outcome, were generated from a bivariate Normal distribution with a 
respective correlation coefficient  chosen to reflect Kendall's τ through the relationship𝜌  𝜌 =
; (Kruskal, 1958)[24]. These values were then rescaled to ensure that the final distributions sin
𝜏𝜋
2
of the generated times are similar to those generated using the copula models; since Kendall's τ is 
based on ranks of variables rather than specific values, the underlying value of T is unaffected by 
such a monotonic transformation. Finally, the values were exponentiated to obtain lognormally 
distributed time-to-event values, and the effect of treatment and the underlying trial-level 
association were incorporated by scaling the generated time-to-event value by the required 
random effects. 
Simulations were run on a Windows 7 64‐bit machine with 4 GB RAM, using macros based on 
SAS software, version 9 for Windows[25].
4. Results
4.1 Individual-Level Surrogacy
In this study, individual-level surrogacy was measured within each trial and an overall estimate 
for the meta-analytic setting was taken as a weighted average across trials, using the trial sample 
size as the weight. The notation  here denotes the weighted meta-analytic estimate. Since 𝑅2𝑋𝑂𝑄
the simulations were designed based on a fixed sample size and proportion of censoring, it is 
expected that weighting by the number of observed OS events would lead to comparable 
conclusions.
Figure 1 illustrates the estimated  values across the scenarios of interest when there are six 𝑅2𝑋𝑂𝑄
trials available for analysis, each containing 120 patients. Each boxplot shows the range of 
estimated values across all simulation runs, with the level of censoring and the underlying 
individual‐level association along the x‐axis. Within the figure, the individual plots display 
results from the TTP endpoint on the top row and PFS endpoint on the bottom row. Horizontal 
































































dashed lines at y= 0.2, 0.5 and 0.8 represent the true individual‐level surrogacy being estimated 
by each set of boxplots.
Across all data generation methods, results based on TTP as the surrogate endpoint (top row) 
demonstrate that the information theory method produces estimates of  that are lower than 𝑅2𝑋𝑂𝑄
the value of τ used in data generation, and this is true across all levels of individual association, 
and for all proportions of censoring. Encouragingly, the estimates increase as τ increases, 
suggesting that whilst they are far from the input value, they do reflect increasing magnitudes of 
association. In further exploration of underlying association levels as high as 0.9, the estimated 
results had a median of approximately 0.45 and never exceeded 0.6, reflecting levels that would 
remain too low to provide sufficient confidence that a surrogate endpoint could be used in future 
clinical trials.  However, the main concern is the very large ranges of results, which increase as 
the true level of association increases. Estimates of medium (τ = 0.5) and high (τ = 0.8) strengths 
of association are widely spread, which hampers interpretation. Coupled with the overall lower 
estimates of individual-level association, it is unlikely that even the strongest surrogates could be 
identified, with estimates of ranging from approximately 0.2 to 0.7 when the true 𝑅2𝑋𝑂𝑄 
association is strong. Importantly, the estimated measures appear to be generally robust to the 
proportion of censoring in the data, which provides confidence that datasets with varying 
amounts of censoring and durations of follow-up can provide consistent results. Further, the 
measure appears to be robust to the method of data generation, suggesting that the method is not 
impacted through the shape of the dependence structure between S and T. 
Results based on PFS as the surrogate endpoint (bottom row) highlight strong similarities to 
those for TTP, indicating that there is little impact from endpoints that are not symmetrical or 
have a natural time-ordering. Across the range of simulation scenarios examined, estimates of 
 are slightly higher than those for TTP, which could be expected based on the definition of 𝑅2𝑋𝑂𝑄
progression-free survival incorporating information related to the true endpoint. Unfortunately, 
the high variability remains, meaning that even for the highest underlying association level of 0.8 
the estimated value could be as low as approximately 0.4, which could convince clinicians and 
regulatory bodies that the surrogate was not worthy of further consideration. 
To determine whether more data can improve estimation and reduce variability, further 
simulations were conducted using a total of ten trials, each containing 500 patients. Given the 
similarity of results between the Gumbel copula and the lognormal approach in the smaller 
Figure 1 Estimated values of  (N=6, n=120)𝑅2𝑋𝑂𝑄
































































sample sizes, only Clayton and lognormal generated data were used to evaluate these larger 
samples, which can be found in Figure 2.
For both TTP and PFS scenarios, the availability of larger clinical trial databases has improved 
estimation, specifically with respect to the variability in estimated values of . The wide 𝑅2𝑋𝑂𝑄
ranges of estimates observed with smaller sample sizes was considered to hinder the 
interpretation of the results, whereas these additional scenarios demonstrate reasonably similar 
estimates across all simulation runs. While variability increases slightly with censoring, the 
results remain interpretable and there is a reduction in the overlap of estimates between true 
underlying surrogacy values, providing confidence that the proportion of censoring in the data 
would not change the conclusions of the analysis. However, it remains evident that even under 
truly strong association, the method cannot reach values of  greater than approximately 0.6 𝑅2𝑋𝑂𝑄
for TTP and 0.8 for PFS. Therefore, while improved variability can be achieved through 
increased data, the underestimation remains of concern and promising surrogates may still be 
overlooked.
4.2 Trial-Level Surrogacy
Figure 3 contains similar boxplots to those for individual‐level surrogacy in Figure 1, with the 
y‐axis now representing trial‐level surrogacy.  Overall, across all simulation scenarios, estimates 
of R2trial were highly variable. Based on TTP (top row), there is a slight upwards trend as the true 
R2trial increases, however this increase is negligible in comparison to the large variability, and 
does not allow for reliable conclusions.  Where there is severe over- or under-estimation 
observed for the TTP scenarios, estimates of R2trial based on PFS as the surrogate endpoint are 
generally overestimated. Across almost all settings, estimates range across the entire [0, 1] 
interval, with median values generally lying in the range of 0.2 to 0.5 for TTP and 0.5 to 0.8 for 
PFS, and there is little that can be concluded from these results. Overall, the information theory 
method cannot be deemed appropriate for use in the setting of small trial numbers, as has been 
observed for other surrogacy approaches[15].
Figure 3 Estimated values of R2trial (N=6, n=120)
Figure 2 Estimated values of  (N=10, n=500)𝑅2𝑋𝑂𝑄
































































As for individual-level surrogacy, a selection of additional simulations were conducted using a 
total of ten trials, each containing 500 patients, to determine whether more data can improve 
estimation. These results can be found in Figure 4, and illustrate that increasing the number of 
trials from six to ten and increasing trial sizes from 120 to 500 patients offers some improvement 
in that the variability of the estimates is reduced. However, across the majority of the scenarios, 
the estimates remain far from the underlying value used in simulation and have highly 
overlapping distributions. While the slight upwards trend as the true R2trial increases remains, the 
high variability and bias in estimation hampers interpretation in a real-life setting. 
4.3 Time-ordered endpoints
The paper by Pryseley et al. (2011) [17] speculates that the information theory method for time-to-
event endpoints can naturally be applied to time-to-event endpoints that have a natural ordering, 
such as when overall survival is the true outcome of interest. Since this has not yet been 
examined in the literature, a selection of scenarios generated for the simulation study described 
here were used to test this assumption by taking the outcome variable to be post-progression 
survival (T −S), with the surrogate outcome accounted for through describing the progression 
status (progression [1] or not [0]) as a binary covariate.
Figure 5 illustrates the estimated  values for the time-ordered approach, again containing six 𝑅2𝑋𝑂𝑄
trials, each containing 120 patients, with 0-30% censoring shown on the x-axis, TTP on the top 
row, PFS on the bottom row, and each level of underlying surrogacy highlighted. 
Across all the scenarios examined, it was found that the proposed adjustment using T-S as the 
outcome variable leads to extremely poor estimation of . Regardless of whether the 𝑅2𝑋𝑂𝑄
surrogate endpoint was TTP or PFS or whether the Clayton and Gumbel-generated data were 
considered, there was no impact on the results, with values of  rarely exceeding a value of 𝑅2𝑋𝑂𝑄
0.2 even for the largest values of τ.  
Figure 4 Estimated values of R2trial (N=10, n=500)
Figure 5 Estimated values of R2XOQ for time-ordered endpoints (N=6, n=120)
































































The most likely cause of the poor performance in this context is that key information relating to 
the surrogate outcome is ignored. In reality, the surrogate outcome includes not only the disease 
status, but also the time at which the disease status changed. The outcome (T-S) does not capture 
the time of disease progression, only the duration of time after progression that a patient 
survived, and so it could be expected that it is not sensitive enough to reliably quantify the 
relationship between disease status and true outcome. It is worth noting that the information 
theory approach is not based on joint modelling of endpoints, and so does not assume any 
endpoint symmetry. The attempt to correct for a problem that does not exist is therefore 
unnecessary, and should not be recommended. Future use of the information theory method 
should therefore maintain the outcome variable T and allow for the assessment of time-ordering 
of endpoints through the use of a time-dependent covariate to represent S.
For completeness, estimation of R2trial based on the time-ordered endpoint structure can be found 
in the Supplementary Results. 
5. Discussion
The main aim of this research was to assess the performance of the information theory approach 
in evaluating surrogacy within a meta-analysis based on time-to-event endpoints. We believe this 
to be the only detailed assessment of the approach in this setting, allowing estimation of both 
individual and trial level surrogacy when based on data from multiple clinical trials. It is also the 
first assessment of the approach with surrogate endpoints that also incorporate data from the true 
clinical endpoint. Finally, it is the only known investigation of the approach in a setting of time-
ordered endpoints, where post-progression survival is used as the outcome measure to account 
for the fact that the surrogate endpoint must always occur prior to the true endpoint.
Based on the numbers of trials included in this study (six or ten), the information theory 
approach was unable to reliably detect the underlying strength of trial level association, and in 
the worst case could lead to false positive results that would incorrectly support an endpoint 
being considered a sufficient surrogate for use in future clinical trials. Minor improvements were 
observed with the larger number of trials, however these were insufficient to recommend the 
method for use. In general, the results described herein demonstrate that the evaluation of 
surrogate endpoints is very challenging when the number of clinical trials is limited, and 
supports the need for collaborative efforts between the pharmaceutical industry and academic 
institutions to ensure that meaningful data can be collated for such research purposes. 
At the individual-level, the results have demonstrated that the information theory approach 
consistently under-estimates the underlying surrogacy strength, regardless of the endpoint, data 
generation method, level of censoring in the dataset or sample size.  That said, the approach 
showed very encouraging results with respect to insensitivity to the proportion of censoring in 
































































the datasets, the dependence structure between S and T and the type of surrogate endpoint. 
However, despite the potential benefits of being easy to estimate and having a unified 
interpretation, the results herein have demonstrated that the information theory method is 
insufficiently accurate to draw meaningful conclusions when applied to small-sample meta-
analyses with time to event surrogate and true endpoints.  Based on recent examples[13,14], trial-
level surrogacy values of at least 0.8 are considered necessary to truly establish a surrogate 
endpoint for future use as a primary endpoint for regulatory and healthcare agency decision 
making. If such a high threshold were also set for individual-level surrogacy then it is highly 
unlikely that the information theory approach would lead to regulatory endorsement of any 
surrogate endpoint, regardless of the underlying strength of association. It should be highlighted 
that the surrogate endpoints selected for investigation in this research are examples reflecting 
commonly used endpoints in oncology clinical trial research. While results are expected to 
translate to time-to-event surrogate endpoints in general, the biological rationale based on the 
disease under study, and the potential for confounding of results through selection of specific 
patient populations or treatment mechanisms, should also be strongly considered when 
considering the plausibility of any surrogate endpoint.
It should be noted that results and conclusions of this research differ to some extent from those 
of Pryseley et al. (2011) [17], who concluded that the method performed acceptably when the 
percentage of censored observations on th  surrogate by the true endpoint is not too high. Upon 
further investigation of the software used for their study (made available by the author), a small 
discrepancy in the data generation formula was identified, meaning that the data were not 
simulated according to the intended strength of association and the reference value of τ used for 
bias calculations was subsequently incorrect. In testing of programming with this anomaly, 
results reported by Pryseley et al. (2011)[17] were able to be replicated, suggesting that this is the 
primary cause of the differences in observed results. Importantly, both simulation studies are 
consistent in that findings demonstrate downward bias for very high values of individual-level 
surrogacy.
The main limitation of the simulation study described here has been noted previously; the true 
underlying individual-level surrogacy cannot be controlled via simulation. Since the 𝑅2𝑋𝑂𝑄 
parameter is calculated from conditional models and is based on a likelihood ratio, each 
generated sample can have a slightly different value. An alternative representation of the 
individual-level surrogacy is therefore needed to ensure that each sample is being compared to an 
intended level of association between endpoints, and for this purpose Kendall's τ was used. The 
impact of this is that bias estimates may be incorrectly over- or under-estimated. However, three 
different data generation algorithms were explored, and the results were broadly consistent 
across all scenarios investigated, therefore the findings are considered to be robust and it is 
reasonable to conclude that the information theory method as currently proposed risks missing 
truly promising surrogate endpoints. 
































































A further limitation of the simulation study is that only one set of treatment effects were 
examined (HR=0.67 for PFS and 0.82 for OS for all trials). In the data generation procedure, a 
change in treatment effect has no impact on the underlying strength of association, however it 
could be possible that a change in treatment effect could cause a difference to the Cox model 
parameters that are estimated within the information theory approach. Stronger treatment effects 
were therefore also considered as a sensitivity analysis for selected scenarios using Clayton-
copula generated data (HR=0.50 for PFS and 0.67 for OS) and demonstrate findings that are 
highly consistent with the originally selected treatment effects, with the median and ranges of 
estimates of  being very similar across all levels of τ (see Supplementary Material). Hence, 𝑅2𝑋𝑂𝑄
the selection of specific treatment effects is not considered to have confounded the results of the 
simulation study. 
Finally, the information theory approach is based on an assumption of proportional hazards, such 
that Cox models can be used to estimate treatment and surrogate covariate coefficients. The data 
generation procedure forced proportional hazards through implementation of a time constant 
treatment effect, and there was no consideration of the impact on modelling when this 
assumption was violated. Since the Cox model can be used with time-dependent covariates, it is 
possible to adjust for some forms of non-proportional hazards, but such settings were not 
investigated in this study. Examination of non-proportional hazards was conducted by Pryseley 
(2009)[26], who concluded that the measure  in a single-trial setting performed acceptably 𝑅2𝑋𝑂𝑄
well when the proportion of censoring was low to moderate, however further work could be 
considered to understand the extent of violation that must be observed for the information theory 
approach to show evidence of significantly deteriorated performance. 
It should be noted that the method investigated in this study, along with many others, makes the 
assumption that the surrogate endpoint is in a single, direct causal pathway of the disease under 
study and the ultimate true clinical outcome, and that all of the treatment effect on the true 
outcome is mediated through the surrogate endpoint.  Such assumptions are unverifiable, and 
development of methodology to estimate the causal effect of surrogates and reduce confounding 
of either alternative disease pathways, or alternative impacts of treatment effect on surrogate and 
true endpoints, will be of increasing importance for future research (Frangakis and Rubin, 2002). 
Overall, results of this simulation study allow us to conclude that the information theory 
approach struggles to reach a level that would enable confidence in the strength of a given 
surrogate endpoint. As a result, caution should be used when applying the information theory 
approach to evaluating surrogate endpoints of a time-to-event nature, primarily because the 
estimates of surrogacy may be substantially lower than the true relationship between surrogate 
and true endpoints. 
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Table 1: Simulation Scenarios
Factor Scenarios under simulation
Surrogate Endpoint Time-to-Progression (TTP), Progression-
Free-Survival (PFS)
True Endpoint Overall Survival (OS), post-progression 
survival (for the time-ordered endpoint only)
Data Generation1 Clayton, Gumbel, Lognormal
Number of trials 6, 10
Number of patients per trial 120, 500
Trial-level association2 0.2, 0.5, 0.8
Individual-level association3 0.2, 0.5, 0.8
Censoring Rate (on T) 0%, 30%
1 Initial simulations considered three data generation methods using 6 trials each containing 120 
patients. Further examination was conducted using 10 trials of 500 patients for the Clayton and 
Lognormal methods only. 
2 When evaluating trial-level surrogacy, individual-level surrogacy is fixed at a value of 0.5.
3 When evaluating individual-level surrogacy, trial-level surrogacy is fixed at a value of 0.5.
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